Skip to main content

Table 6 Multivariate Analysis in neoadjuvantly treated patients with gastric cancer without AEG II, III (UICC 7th)

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

   HR 95% CI p
R R0 1.00   0.001
  R1/2 3.40 1.7-6.8  
Clinical response yes 1.00   0.021
  no 10.30 1.4-75.5  
MTHFR A1298C AA 1.00   0.028
  AC 2.80 1.3-5.9  
  CC 2.00 0.5-7.6